• TNBC0
• HER 2+0
• HR+/HER2 neg1
• ER+0

• Protocols

• NCI10495

  OPEN TO ACCRUAL

  Ph1 Study of DS-8201a in Combination with Neratinib in Solid Tumors with HER2 Alterations
  
  

• UW23151

  OPEN TO ACCRUAL

  Ph 1 Study of SynKIR-110, CAR-T Therapy in Pts w/ MSLN-Expressing OC, CCA, or Mesothelioma